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Dear Sir,
We read with interest the comments of Dr. Tfelt-Hansen
[1] regarding our three recently published randomized
controlled trials comparing patients’ preference (primary
endpoint) and efficacy (secondary endpoints) of frovatrip-
tan 2.5 mg versus zolmitriptan 2.5 mg [2], rizatriptan
10 mg [3] and almotriptan 12.5 mg [4], and the meta-
analysis of pooled individual data from the three studies
[5]. In all studies frovatriptan showed similar preference
and short-term efficacy outcomes (pain relief and pain-free
episodes at 2 h) with respect to the other three triptans.
The questions put by Dr. Tfelt-Hansen sound appropri-
ate. Doubts are raised on the usefulness of head-to-head
preference trials of triptans and on the actual translation of
their results into the clinical practice. We agree that
patients may probably switch over time from one triptan to
another because of individual preference, which might not
be in line with results of randomized, controlled, compar-
ative studies. However, the availability of results of head-
to-head preference and efficacy trials may help physicians
to make a first choice which might be very close to the
actual patient’s preference. We should remind that some
evidence on triptan preference in clinical practice does
exist, even if we recognize that a tighter link between trials
and clinical practice might be developed, for instance, by
appropriate surveys [6, 7].
It is true that some guidelines usually refer to simple
(and cheaper) oral analgesics and anti-emetics or pro-
kinetic as the first line treatment of acute migraine, esca-
lating to a (more expensive) triptan if this approach fails [8,
9]. This might sound reasonable in terms of the efficacy,
because, as mentioned by Dr. Telft-Hansen, a meta-anal-
ysis showed that aspirin and sumatriptan act similarly in
migraineurs [10]. More recently a publication from the
same group showed a good efficacy of aspirin in treatment
of acute migraine of moderate or severe intensity [11].
However, we think that a comparative study with suma-
triptan, namely the oldest among triptans, might not be
ideal, because newer triptans have been proved to be more
effective than sumatriptan, with differences in the onset
time of headache relief according to the characteristics of
the studied triptan [12, 13]. Even though the efficacy of
some triptans and aspirin might be similar in the acute
phase of migraine, it is undisputable that triptans have a
more definite place in treatment of chronic and recurrent
migraine attacks in the most published guidelines. In
addition, oral analgesics, like aspirin, are not an exempt
from adverse events, as shown by a recent meta-analysis
[14]. At the light of the current evidence we think that
choice of use of non-steroidal anti-inflammatory-drugs or
triptans for treatment of migraine headache should be
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based on several considerations, including characteristics
of migraine, drug efficacy, patient’s preference and drug
safety in the individual subject. Unfortunately, only a few
of these aspects are taken into account in the current
recommendations.
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